Driving efficient immuno-oncology drug development with optimal preclinical model selection

Rapid advances in immuno-oncology (IO) over the last decade have seen the emergence of hundreds of new immunotherapy companies, with a wealth of investigational therapies and combination therapies entering the pipeline. From 2017 to 2020 alone, the number of candidates grew by 223%, and there are more than 4,700 therapies in development, many of which are in clinical trials.